NCT07475923

Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)

• Status: Withdrawn
• Phase: —
• Study type: Observational
• Enrollment: 0 (actual)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To learn about changes in ctDNA during the diagnosis, treatment, and post-treatment surveillance of EBC.

Detailed description

Primary Objectives To describe the dynamic changes of ctDNA by binary MRD status (positive/negative) using the Myriad Genetics Precise MRD assay during the spectrum of diagnosis, treatment (neoadjuvant and adjuvant), and post-therapy surveillance of EBC in subgroups of interest. Secondary Objectives To describe the dynamic changes of ctDNA by continuous quantitative tumor fraction using the Myriad Genetics Precise MRD assay during the spectrum of diagnosis, treatment (neoadjuvant and adjuvant), and post-therapy surveillance of EBC in subgroups of interest.

Conditions

• Molecular Surveillance
• Breast Cancer
• ctDNA
• MRD
• Observational Study

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Blood draw for the laboratory assessment	Blood will be drawn up to every cycle during neoadjuvant treatment
DRUG	Neoadjuvant treatment	Given by IV

Timeline

• Start date: 2026-04-09
• Primary completion: 2026-04-09
• Completion: 2026-04-09
• First posted: 2026-03-17
• Last updated: 2026-04-16